NTLA
Intellia Therapeutics, Inc. · Healthcare
Insiders bought $1.4M of Intellia Therapeutics, Inc. in the last 12 months
1 insider bought on 1 day.
NTLA over the last year
Largest buyers, last 12 months
NTLA after insider buys
3 months after each buy, from the first price a copier could get.
2 buys have 3 months of prices so far. A record shows here at 3.
Congress
Members reported 2 trades in NTLA since 2023.
Every filing
107 insider filings since 2016, newest first
John M Leonard · President and CEO
David Lebwohl · EVP and Chief Medical Officer
Laura Sepp-Lorenzino · EVP and Chief Scientific Officer
Glenn Goddard · EVP and CFO
Jean Francois Formela · Director
Jean Francois Formela · Director
Jean Francois Formela · Director
Jean Francois Formela · Director
Jean Francois Formela · Director
Caroline Dorsa · Director
John M Leonard · President and CEO
Jose E Rivera · EVP and General Counsel
Jean Francois Formela · Director
John M Leonard · President and CEO
Jose E Rivera · EVP and General Counsel
John M Leonard · President and CEO
Jose E Rivera · EVP and General Counsel
John M Leonard · President and CEO
Andrew Schiermeier · EVP and COO
Jose E Rivera · EVP and General Counsel
Perry A Karsen · Director
Jose E Rivera · EVP and General Counsel
John M Leonard · President and CEO
John M Leonard · President and CEO
John M Leonard · President and CEO
Jose E Rivera · EVP and General Counsel
John M Leonard · President and CEO
Jose E Rivera · EVP and General Counsel
Jose E Rivera · EVP and General Counsel
John M Leonard · President and CEO
Jose E Rivera · EVP and General Counsel
John M. Leonard · President and CEO
Jose E Rivera · EVP and General Counsel
John M. Leonard · President and CEO
Jose E Rivera · EVP and General Counsel
John M. Leonard · President and CEO
Jose E Rivera · EVP and General Counsel
John M. Leonard · President and CEO
Jose E Rivera · EVP and General Counsel
Andrew Schiermeier · EVP, Dev, Corp Strategy
Jean Francois Formela · Director
Jean Francois Formela · Director
Jean Francois Formela · Director
John M. Leonard · President and CEO
Jean Francois Formela · Director
Caribou Biosciences, Inc. · 10% owner
Novartis Institutes For Biomedical Research, Inc. · 10% owner
Nessan Bermingham · President and CEO
Jean Francois Formela · Director
Atlas Venture Fund Ix, L.P. · 10% owner
About Intellia Therapeutics, Inc.
Intellia Therapeutics, Inc. operates as a clinical-stage genome editing company focused on developing potentially curative therapeutics using CRISPR/Cas9-based technologies. The company offers clustered, regularly interspaced short palindromic repeats (CRISPR)/CRISPR associated 9 (Cas9) technology for genome editing. The company provides a modular platform, to advance in vivo and ex vivo therapies for diseases. The company's in vivo product candidates include nexiguran ziclumeran, or NTLA-2001 for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema. Additionally, it offers product candidates for the treatment of immuno-oncology and autoimmune diseases, and multiple in vivo programs to address diseases with significant unmet medical need by delivering gene editing therapeutics to organs outside the liver. The company has license and collaboration agreement with AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of various of B cell-mediated autoimmune diseases; ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer; and ReCode Therapeutics, Inc. to develop novel genomic medicines for the treatment of cystic fibrosis. It also has collaboration agreements with Regeneron Pharmaceuticals, Inc., SparingVision SAS, and Rewrite Therapeutics Inc. The company was formerly known as AZRN, Inc. and changed its name to Intellia Therapeutics, Inc. in July 2014. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
Filings come from SEC EDGAR and prices from daily closes. Not investment advice.